MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562474 | Name: Lovastatin Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lovastatin Sodium is an inhibitor of HMG-CoA reductase.

Chemical Structure

Lovastatin Sodium
Lovastatin Sodium
CAS#75225-50-2 (sodium)

Theoretical Analysis

MedKoo Cat#: 562474

Name: Lovastatin Sodium

CAS#: 75225-50-2 (sodium)

Chemical Formula: C24H37NaO6

Exact Mass: 0.0000

Molecular Weight: 444.54

Elemental Analysis: C, 64.84; H, 8.39; Na, 5.17; O, 21.59

Price and Availability

Size Price Availability Quantity
5mg USD 300.00 2 weeks
10mg USD 550.00 2 weeks
25mg USD 950.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
75225-50-2 (sodium) 75330-75-5
Synonym
Lovastatin Sodium; Lovastatin Na; Mevinolin sodium; 6-α-Methylcompactin sodium;
IUPAC/Chemical Name
Sodium (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
InChi Key
LXZBFUBRYYVRQJ-AXHZAXLDSA-M
InChi Code
InChI=1S/C24H38O6.Na/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28;/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28);/q;+1/p-1/t14-,15-,16-,18+,19+,20-,21-,23-;/m0./s1
SMILES Code
O=C([O-])C[C@H](O)C[C@H](O)CC[C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@H](OC([C@@H](C)CC)=O)[C@]12[H].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a Ki of 0.6 nM.
In vitro activity:
MTT assay was employed to determine whether FaDu cell viability is altered in the presence of lovastatin. As shown in Fig. 1a, lovastatin concentration-dependently decreased FaDu cell viability after 24 h exposure. Longer exposure to lovastatin (48 h) further decreased FaDu cell viability (Fig. 1a). To determine whether lovastatin-decreased FaDu cell viability was a result of cell cycle arrest or apoptosis, flowcytometry was used. As shown in Fig. 1b, the percentage of propidium iodide (PI)-stained cells in the S region was significantly decreased in FaDu cells after exposure to lovastatin for 24 h. In addition, lovastatin increased the percentage of PI-stained cells in the G0/G1 region (Fig. 1b). Moreover, 24 h treatment of lovastatin only slightly induced cell apoptosis (sub-G1 region) (Fig. 1b). However, lovastatin significantly induced apoptosis in FaDu cells after 48 h exposure of lovastatin (Fig. 1c). To detect apoptosis in FaDu cells exposed to lovastatin, flowcytometry with PI and annexin V-FITC double-labeling was also employed. As shown in Fig. 1d, lovastatin increased the percentage of early apoptotic cells (annexin V+PI− cells) and advanced apoptotic cells and/or necrotic cells (annexin V+PI+ cells) after 48 h exposure. It was next determined whether lovastatin activates caspase 3. As shown in Fig. 1e, lovastatin increased the cleaved (active) form of caspase 3 and PARP, a selective caspase 3 substrate. These findings suggest that lovastatin induced apoptosis and inhibited cell proliferation in FaDu cells. Reference: Sci Rep. 2016; 6: 25082. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848532/
In vivo activity:
To determine the effect of LOV administered prior to viral (DENV-2-infected) inoculation (pre-treatment), groups of six mice were treated with a single dose (24 hrs) or three doses (72, 48 and 24 hrs) before inoculation with DENV-2 (Figure 1). Moreover, three different types of control groups were used (See Materials and Methods section). In the group pre-treated with three LOV doses, there was a significant 21.8% reduction in viremia compared to the control group without LOV (p<0.001) (Table 1). Viremia was not significantly reduced in mice treated with a single LOV dose (reduction of 3.0%) (Figure 3A). In the groups treated with one or three LOV doses, weight loss was reduced compared to the control group without LOV (18.6% and 15.1%, respectively, compared to 24.0%) (Figure 3B). Based on Kaplan-Meier analyses, significant increase of survival in the groups treated with one or three doses compared to the control group without LOV (p<0.05) was found. This result is consistent with the average survival rates, which significantly increased (p<0.001) in the groups treated with one or three doses compared to the control group without LOV (7.33±1.0 and 7.17±0.9 days, respectively, versus 4.8±1.6 days) (Figure 3C–D). The LOV treatment alone did not affect the weight or survival time of treated mice in the control group. However, despite the reductions in viremia and weight loss and the increased survival rate observed following LOV treatment, some animals in this experimental group (pre-treatment) developed severe paralysis and were sacrificed by CO2 asphyxiation the moment these signs started to develop.These results suggest that the effect of LOV on viremia depends on the timing of treatment and on the number of doses administered. Reference: PLoS One. 2014; 9(2): e87412. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931612/
Solvent mg/mL mM
Solubility
DMF 10.0 22.50
DMSO 11.3 25.31
Ethanol 10.0 22.50
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 444.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yen CS, Chen JC, Chang YF, Hsu YF, Chiu PT, Shiue C, Chuang YF, Ou G, Hsu MJ. Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. Sci Rep. 2016 Apr 28;6:25082. doi: 10.1038/srep25082. PMID: 27122225; PMCID: PMC4848532. 2. Terada Y, Inoshita S, Nakashima O, Yamada T, Kuwahara M, Sasaki S, Marumo F. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol. 1998 Dec;9(12):2235-43. doi: 10.1681/ASN.V9122235. PMID: 9848777. 3. Fernandez K, Spielbauer KK, Rusheen A, Wang L, Baker TG, Eyles S, Cunningham LL. Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020 Apr;389:107905. doi: 10.1016/j.heares.2020.107905. Epub 2020 Feb 6. PMID: 32062294; PMCID: PMC7080598. 4. Martinez-Gutierrez M, Correa-Londoño LA, Castellanos JE, Gallego-Gómez JC, Osorio JE. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One. 2014 Feb 21;9(2):e87412. doi: 10.1371/journal.pone.0087412. PMID: 24586275; PMCID: PMC3931612.
In vitro protocol:
1. Yen CS, Chen JC, Chang YF, Hsu YF, Chiu PT, Shiue C, Chuang YF, Ou G, Hsu MJ. Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. Sci Rep. 2016 Apr 28;6:25082. doi: 10.1038/srep25082. PMID: 27122225; PMCID: PMC4848532. 2. Terada Y, Inoshita S, Nakashima O, Yamada T, Kuwahara M, Sasaki S, Marumo F. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol. 1998 Dec;9(12):2235-43. doi: 10.1681/ASN.V9122235. PMID: 9848777.
In vivo protocol:
1. Fernandez K, Spielbauer KK, Rusheen A, Wang L, Baker TG, Eyles S, Cunningham LL. Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020 Apr;389:107905. doi: 10.1016/j.heares.2020.107905. Epub 2020 Feb 6. PMID: 32062294; PMCID: PMC7080598. 2. Martinez-Gutierrez M, Correa-Londoño LA, Castellanos JE, Gallego-Gómez JC, Osorio JE. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One. 2014 Feb 21;9(2):e87412. doi: 10.1371/journal.pone.0087412. PMID: 24586275; PMCID: PMC3931612.
1: Rahim MHA, Hasan H, Harith HH, Abbas A. The effect of viscosity, friction, and sonication on the morphology and metabolite production from Aspergillus terreus ATCC 20542. Bioprocess Biosyst Eng. 2017 Dec;40(12):1753-1761. doi: 10.1007/s00449-017-1830-y. Epub 2017 Sep 6. PubMed PMID: 28879627. 2: Wang K, Wang Y, Zhao X, Li Y, Yang T, Zhang X, Wu X. Sustained release of simvastatin from hollow carbonated hydroxyapatite microspheres prepared by aspartic acid and sodium dodecyl sulfate. Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:565-571. doi: 10.1016/j.msec.2017.02.066. Epub 2017 Feb 15. PubMed PMID: 28415500. 3: Medeiros VF, Azevedo ÍM, Carvalho MD, Egito ES, Medeiros AC. Effects of cococonut water and simvastatin in the treatment of sepsis and hemorrhagic shock in rats. Acta Cir Bras. 2016 Dec;31(12):826-833. doi: 10.1590/S0102-865020160120000008. PubMed PMID: 28076507. 4: Brown JP, Hall D, Frank CL, Wallace K, Mundy WR, Shafer TJ. Editor's Highlight: Evaluation of a Microelectrode Array-Based Assay for Neural Network Ontogeny Using Training Set Chemicals. Toxicol Sci. 2016 Nov;154(1):126-139. Epub 2016 Aug 4. PubMed PMID: 27492221. 5: Balata GF, Zidan AS, Abourehab MA, Essa EA. Rapid disintegrating tablets of simvastatin dispersions in polyoxyethylene-polypropylene block copolymer for maximized disintegration and dissolution. Drug Des Devel Ther. 2016 Oct 3;10:3211-3223. eCollection 2016. PubMed PMID: 27757012; PubMed Central PMCID: PMC5055116. 6: Wei TT, Lin YT, Tseng RY, Shun CT, Lin YC, Wu MS, Fang JM, Chen CC. Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor. Clin Cancer Res. 2016 Aug 15;22(16):4158-69. doi: 10.1158/1078-0432.CCR-15-2379. Erratum in: Clin Cancer Res. 2018 Jan 15;24(2):499. PubMed PMID: 27528734. 7: Kang D, Shao Y, Yin X, Xiao J, Rao T, Shen B, Chen H, Zhu Z, Wang G, Liang Y. Bioanalytical assay development and validation for simultaneous quantification of five schisandra lignans in rat primary hepatocytes based on LC-MS/MS: application to a real-time uptake study for Schisandra Lignan Extract. Biomed Chromatogr. 2017 Feb;31(2). doi: 10.1002/bmc.3797. Epub 2016 Aug 16. PubMed PMID: 27459903. 8: Duan H, Zhang J, Li L, Bao S. Effect of Simvastatin on Proliferation of Vascular Smooth Muscle Cells During Delayed Cerebral Vasospasm After Subarachnoid Hemorrhage. Turk Neurosurg. 2016;26(4):538-44. doi: 10.5137/1019-5149.JTN.13650-15.1. PubMed PMID: 27400100. 9: Ayalasomayajula S, Han Y, Langenickel T, Malcolm K, Zhou W, Hanna I, Alexander N, Natrillo A, Goswami B, Hinder M, Sunkara G. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). J Clin Pharm Ther. 2016 Aug;41(4):424-31. doi: 10.1111/jcpt.12408. Epub 2016 Jun 19. PubMed PMID: 27321165. 10: Marsh A, Casey-Green K, Probert F, Withall D, Mitchell DA, Dilly SJ, James S, Dimitri W, Ladwa SR, Taylor PC, Singer DR. Simvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 Protein. PLoS One. 2016 Feb 10;11(2):e0148266. doi: 10.1371/journal.pone.0148266. eCollection 2016. PubMed PMID: 26863535; PubMed Central PMCID: PMC4749215. 11: Mihaila RG. A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Dec;159(4):519-26. doi: 10.5507/bp.2015.060. Epub 2015 Nov 27. Review. PubMed PMID: 26725705. 12: Dhiman N, Awasthi R, Jindal S, Khatri S, Dua K. Development of Bilayer Tablets with Modified Release of Selected Incompatible Drugs. Polim Med. 2016 Jan-Jun;46(1):5-15. doi: 10.17219/pim/62511. PubMed PMID: 28397414. 13: Rezvanian M, Amin MCIM, Ng SF. Development and physicochemical characterization of alginate composite film loaded with simvastatin as a potential wound dressing. Carbohydr Polym. 2016 Feb 10;137:295-304. doi: 10.1016/j.carbpol.2015.10.091. Epub 2015 Nov 2. PubMed PMID: 26686133. 14: Craye G, Löbmann K, Grohganz H, Rades T, Laitinen R. Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying. Molecules. 2015 Dec 3;20(12):21532-48. doi: 10.3390/molecules201219784. PubMed PMID: 26633346. 15: Zand L, Torres VE, Larson TS, King BF, Sethi S, Bergstralh EJ, Angioi A, Fervenza FC. Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016 Aug;31(8):1290-5. doi: 10.1093/ndt/gfv394. Epub 2015 Nov 27. PubMed PMID: 26614268; PubMed Central PMCID: PMC5009420. 16: Okuyama-Dobashi K, Kasai H, Tanaka T, Yamashita A, Yasumoto J, Chen W, Okamoto T, Maekawa S, Watashi K, Wakita T, Ryo A, Suzuki T, Matsuura Y, Enomoto N, Moriishi K. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci Rep. 2015 Nov 23;5:17047. doi: 10.1038/srep17047. PubMed PMID: 26592202; PubMed Central PMCID: PMC4655410. 17: Surve SM, Acharya AB, Thakur SL. Efficacy of subgingivally delivered atorvastatin and simvastatin as an adjunct to scaling and root planing. Drug Metab Pers Ther. 2015 Dec;30(4):263-9. doi: 10.1515/dmpt-2015-0024. PubMed PMID: 26552068. 18: Đanić M, Pavlović N, Stanimirov B, Vukmirović S, Nikolić K, Agbaba D, Mikov M. The influence of bile salts on the distribution of simvastatin in the octanol/buffer system. Drug Dev Ind Pharm. 2016;42(4):661-7. doi: 10.3109/03639045.2015.1067626. Epub 2015 Jul 23. PubMed PMID: 26204349. 19: Patel DS, Pipaliya RM, Surti N. Liquisolid Tablets for Dissolution Enhancement of a Hypolipidemic Drug. Indian J Pharm Sci. 2015 May-Jun;77(3):290-8. PubMed PMID: 26180274; PubMed Central PMCID: PMC4502143. 20: Du X, Zhang C, Guo W, Jin W, Liang Z, Yan X, Guo Z, Liu Y, Yang D. Nitric Oxide Plays a Central Role in Water Stress-Induced Tanshinone Production in Salvia miltiorrhiza Hairy Roots. Molecules. 2015 Apr 24;20(5):7574-85. doi: 10.3390/molecules20057574. PubMed PMID: 25919278.

View History

ENT 25788

ENT 25788

Enprostil

Enprostil

Fenprostalene

Fenprostalene

Fluphenazine enanthate

Fluphenazine enanthate

Fepradinol HCl

Fepradinol HCl

Depreotide

Depreotide